Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515049 | 0.81 | SMN1; SMN2 (0.45) | ABCB1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7284886 | 0.78 | HSD17B10 (0.44) | ABCB1NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL95381 | 0.76 | TSHR (0.44) | RAB9ASMN1; SMN2 | |
| SCHEMBL6238419 | 0.74 | JAK2 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5758916 | 0.74 | GABRA1 (0.40) | — | |
| SCHEMBL7285472 | 0.74 | HTR1A (0.49) | ALDH1A1 | |
| SCHEMBL5757761 | 0.74 | SLC6A3 (0.37) | SMN1; SMN2 | |
| SCHEMBL5756958 | 0.74 | GABRA1 (0.39) | ALDH1A1 | |
| SCHEMBL9564266 | 0.74 | PDE10A (0.53) | ALDH1A1 | |
| SCHEMBL5758315 | 0.74 | TAAR1 (0.45) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | claimed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | claimed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | claimed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-1104403-B1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PROD INC (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MCCLURE KIM F (US) | 2003-01-09 | — | — | US | disclosed |
| US-6329397-B1 | TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. | PFIZER | 2001-12-11 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0874629-A4 | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS | DU PONT MERCK PHARMA (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0874629-A1 | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997023212-A1 | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | ABCB1 72/4885NPC1 1072/4885RAB9A 399/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | ABCB1 73/4885NPC1 1698/4885RAB9A 502/4885 |
| US-20030008901-A1 | Hydroxy pipecolate hydroxamic acid derivatives | MMP1, MMP10, MMP3 | ABCB1 706/4885NPC1 3537/4885RAB9A 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.